Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria

Lucca, Ilaria; Hofbauer, Sebastian L.; Haitel, Andrea; Susani, Martin; Shariat, Shahrokh F.; Klatte, Tobias; Martino, Michela de

doi:10.3892/ol.2019.10330

Cited by 4 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BCa is a malignant tumor with a high incidence and recurrence rate. Lucca et al [119] performed a gene array-based analysis to evaluate the expression of HDAC9 in RNA samples obtained from voided urine from patients with asymptomatic microscopic hematuria who were diagnosed with urothelial BCa. They found that HDAC9 mRNA was upregulated in urothelial BCa patients.…”

Section: Bladder Cancer (Bca)mentioning

confidence: 99%

Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer

2021

View full text Add to dashboard Cite

Background HDAC9 (histone deacetylase 9) belongs to the class IIa family of histone deacetylases. This enzyme can shuttle freely between the nucleus and cytoplasm and promotes tissue-specific transcriptional regulation by interacting with histone and non-histone substrates. HDAC9 plays an essential role in diverse physiological processes including cardiac muscle development, bone formation, adipocyte differentiation and innate immunity. HDAC9 inhibition or activation is therefore a promising avenue for therapeutic intervention in several diseases. HDAC9 overexpression is also common in cancer cells, where HDAC9 alters the expression and activity of numerous relevant proteins involved in carcinogenesis. Conclusions This review summarizes the most recent discoveries regarding HDAC9 as a crucial regulator of specific physiological systems and, more importantly, highlights the diverse spectrum of HDAC9-mediated posttranslational modifications and their contributions to cancer pathogenesis. HDAC9 is a potential novel therapeutic target, and the restoration of aberrant expression patterns observed among HDAC9 target genes and their related signaling pathways may provide opportunities to the design of novel anticancer therapeutic strategies.

show abstract

Section: Bladder Cancer (Bca)mentioning

confidence: 99%

Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer

2021

View full text Add to dashboard Cite

show abstract

“…Therefore, the balance of HATs and HDACs influences transcriptional activity, which is one of the major regulators in epigenetics. 71 Lucca et al 72 collected and analysed 227 urine RNA samples from 227 patients with asymptomatic microscopic haematuria (AMH), and 18 random samples were chosen to proceed with gene array analysis. The results showed a significant difference in the expression of HDAC9, HDAC3, tRNA-methyltransferase 1 (TRDMT1) and DNA methyltransferase 1 (DNMT1) among the BC group and controls.…”

Section: Histone Modificationsmentioning

confidence: 99%

“…Therefore, the balance of HATs and HDACs influences transcriptional activity, which is one of the major regulators in epigenetics 71 . Lucca et al 72 . collected and analysed 227 urine RNA samples from 227 patients with asymptomatic microscopic haematuria (AMH), and 18 random samples were chosen to proceed with gene array analysis.…”

Section: Epigenetic Features In Bcmentioning

confidence: 99%

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

Zeng

Wang

et al. 2023

Clinical and Translational Dis

View full text Add to dashboard Cite

Urine‐based liquid biopsy has emerged as a non‐invasive and effective tool for early screening and diagnosis of bladder cancer. This review provides a comprehensive overview of the current urine‐based biomarkers and methods for the detection and monitoring of bladder cancer. We focus on biomarkers including tumour DNAs, proteins, microbiome, tumour RNAs, long non‐coding RNAs, transfer RNA‐derived fragments, messenger RNAs, microRNAs, circular RNAs, exosomes and extrachromosomal circular DNA.

show abstract

“…HDAC3 microRNA in urine has also been shown to be significantly higher in patients with urothelial bladder cancer than in control patients [ 38 ]. HDACs have also been studied in non-urothelial bladder cancer, with one study finding HDAC4, HDAC7, and HDAC9 to be overexpressed in basal-squamous bladder cancer [ 39 ].…”

Section: Epigenetics and Bladder Cancermentioning

confidence: 99%

New Approaches to Targeting Epigenetic Regulation in Bladder Cancer

Thompson

Lawrentschuk

Bolton

2023

Cancers

View full text Add to dashboard Cite

Epigenetics is a growing field and in bladder cancer, it is of particular interest in advanced or metastatic disease. As opposed to genetic mutations in which the nucleotide sequence itself is altered, epigenetic alterations refer to changes to the genome that do not involve nucleotides. This is of great interest in cancer research because epigenetic alterations are reversible, making them a promising target for pharmacological agents. While chemoimmunotherapy is the mainstay for metastatic disease, there are few alternatives for patients who have progressed on first- or second-line treatment. By targeting reversible epigenetic alterations, novel epigenetic therapies are important potential treatment options for these patients. A search of clinical registries was performed in order to identify and collate epigenetic therapies currently in human trials. A literature search was also performed to identify therapies that are currently in preclinical stages, whether this be in vivo or in vitro models. Twenty-five clinical trials were identified that investigated the use of epigenetic inhibitors in patients with bladder cancer, often in combination with another agent, such as platinum-based chemotherapy or pembrolizumab. The main classes of epigenetic inhibitors studied include DNA-methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and histone methyltransferase (HMT) inhibitors. At present, no phase 3 clinical trials have been registered. Few trials have published results, though DNMT inhibitors have shown the most promise thus far. Many patients with advanced or metastatic bladder cancer have limited treatment options, particularly when first- or second-line chemoimmunotherapy fails. Epigenetic alterations, which are common in bladder cancer, are potential targets for drug therapies, and these epigenetic agents are already in use for many cancers. While they have shown promise in pre-clinical trials for bladder cancer, more research is needed to assess their benefit in clinical settings.

show abstract

Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria

Cited by 4 publications

References 35 publications

Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer

Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

New Approaches to Targeting Epigenetic Regulation in Bladder Cancer

Contact Info

Product

Resources

About